EU Demands Pfizer Offload Infliximab Biosimilar In Hospira Buy
This article was originally published in Scrip
Executive Summary
The EU Commission is backing Pfizer Inc.'s planned purchase of US-based generics firm Hospira Inc. provided the big pharma divest some sterile injectable drugs as well as its own biosimilar version of Johnson & Johnson and Merck & Co.'s Remicade (infliximab) which is currently under development.
You may also be interested in...
Pfizer's Infliximab Biosimilar Approved In US But Won't Launch Against Inflectra
Ixifi (infliximab-qbtx), which references Janssen's Remicade, marks first US approval of a biosimilar developed entirely by Pfizer; big pharma says it is not currently planning to launch Ixifi because it remains "committed" to marketing Celltrion's Inflectra.
Pfizer's Infliximab Biosimilar Approved In US But Won't Launch Against Inflectra
Ixifi (infliximab-qbtx), which references Janssen's Remicade, marks first US approval of a biosimilar developed entirely by Pfizer; big pharma says it is not currently planning to launch Ixifi because it remains "committed" to marketing Celltrion's Inflectra.
Biosimilars: The Unlikely Hero Of Specialty Pharma?
In the patent cliff musical chairs game, the music has stopped and generic companies like Mylan and Teva are looking for the next growth driver. While this seems to be biosimilars, it appears that innovator companies who are used to developing biologics, are already sitting in their seats.